Dose-Escalation Study of AL-39324 Suspension versus Lucentis for the Treatment of Exudative AMD

Registry ID
EUCTR2009-015681-55
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
Alcon Research, Ltd.
Start date
2010-03-18
Completion date
2011-06-20
Last update
2026-08-16

Conditions

Summary

The objective of this study is to assess the safety, tolerability and the effects of treatment on ocular outcomes following a single intravitreal administration of AL-39324 suspension in subjects with exudative AMD.

Locations

View on source registry